Evidence map›Paper›PMID 42185401›Full record

ArticleScientific reports2026

Expression of LIFR in tumor and SHOC2, YAP1 in plasma mRNA as potential biomarkers in KRAS

Ana Giménez-Capitán, Daniel Olmo-Gónzalez, Elizabeth Martínez-Pérez, Andrés Aguilar-Hernández, María González-Cao, Roxana Reyes, Irene Moya, Víctor Albarrán, Ivana Sullivan, Joselyn Valarezo and 5 more

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ana Giménez-CapitánPangaea Oncology Lab, Dexeus University Hospital, Barcelona, Spain.
Daniel Olmo-GónzalezFaculty of Biology, Department of Biochemistry and Molecular Biomedicine, University of Barcelona, Barcelona, Spain.
Elizabeth Martínez-PérezPangaea Oncology Lab, Dexeus University Hospital, Barcelona, Spain.
Andrés Aguilar-HernándezInstituto Oncológico Dr. Rosell, Dexeus University Hospital, Barcelona, Spain.
María González-CaoInstituto Oncológico Dr. Rosell, Dexeus University Hospital, Barcelona, Spain.
Roxana ReyesIntituto Oncológico Dr. Rosell, Teknon Medical Center, Barcelona, Spain.
Irene MoyaIntituto Oncológico Dr. Rosell, General University Hospital of Catalonia, Barcelona, Spain.
Víctor AlbarránIntituto Oncológico Dr. Rosell, Teknon Medical Center, Barcelona, Spain.
Ivana SullivanPangaea Oncology Lab, Dexeus University Hospital, Barcelona, Spain.
Joselyn ValarezoPangaea Oncology Lab, Dexeus University Hospital, Barcelona, Spain.
Beatriz GarcíaPangaea Oncology Lab, Dexeus University Hospital, Barcelona, Spain.
Ruth RománPangaea Oncology Lab, Dexeus University Hospital, Barcelona, Spain.
Clara Mayo De Las CasasPangaea Oncology Lab, Dexeus University Hospital, Barcelona, Spain.
Miguel Ángel Molina-VilaPangaea Oncology Lab, Dexeus University Hospital, Barcelona, Spain.
Rafael RosellPangaea Oncology Lab, Dexeus University Hospital, Barcelona, Spain. rrosell@oncorosell.com.

Funding

This work was supported by generous funding from Julián Santamaría Valiño to the IOR Foundation. no grant ID
6 · The paper itself

Abstract

Advanced non-small cell lung cancer (NSCLC) harboring KRAS

Indexed as

Adaptor Proteins, Signal TransducingBiomarkers, TumorCarcinoma, Non-Small-Cell LungIntracellular Signaling Peptides and ProteinsLung NeoplasmsProto-Oncogene Proteins p21(ras)RNA, MessengerTranscription FactorsAgedFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedMutationYAP-Signaling ProteinsAdaptor Proteins, Signal TransducingBiomarkers, TumorIntracellular Signaling Peptides and ProteinsKRAS protein, humanProto-Oncogene Proteins p21(ras)RNA, MessengerTranscription FactorsYAP1 protein, humanYAP-Signaling Proteinsacquired resistance mechanismscirculating plasma biomarkersgene expression profilingKRAS G12C inhibitorsLIFRnon-small cell lung cancer (NSCLC)

Identifiers

PMID42185401
PMCPMC13439181

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.